Science Progress | Where science, technology, and progressive policy meet

U.S. Stem Cell Ruling Invites Asian Competition

Stem Cell Lab In Tianjin SOURCE: AP Photo/Greg Baker Tianjin's Union Stem Cell and Gene Engineering Ltd. is one of many companies in China and across Asia who may benefit if the recent injunction on U.S. embryonic stem cell grants prevents thousands of researchers from doing their work here.

The ink had barely dried on last week’s U.S. court decision barring the National Institutes of Health from funding embryonic stem cell grants when I received this message from the second annual Stem Cells Asia Regenerative Medicine Congress, which meets in Seoul on October 26 through 28:

Dear Jonathan Moreno,

‘Halt to U.S. Stem Cell Funding May Thwart Search for New Cures’ — Bloomberg News

This is one of the most pertinent reasons why stakeholders of the stem cells arena are now moving to Asia to leverage on Asia’s laissez-faire regulations and capitalize on Asia’s growth potential in stem cell research and application.

And I was in fact quoted in that Bloomberg News story as follows:

“This is a catastrophe. “…It’s now possible that the United States is now taken out of embryonic stem cell research.”

To read the rest of this article, please visit the San Jose Mercury. To read more about how Asia will benefit from the recent injunction on U.S. stem cell research, go here. To read about how the US will fall behind, go here.

Comments on this article

By clicking and submitting a comment I acknowledge the Science Progress Privacy Policy and agree to the Science Progress Terms of Use. I understand that my comments are also being governed by Facebook's Terms of Use and Privacy Policy.